Novo Nordisk A/S : The underlying trend is in force again
Published july 18, 2019 at 09:20 am edt
By
| Entry price | Target | Stop-loss | Potential |
|---|
|
DKK 321.65 |
DKK 348 |
DKK 308.5 |
+8.19% |
|---|
The current trading zone is interesting to the point that investors should pay attention to the stock and anticipate a return of the underlying upward trend.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
● The share is getting closer to its long-term support in weekly data, at DKK 310, which offers good timing for buyers.
● The group's activity appears highly profitable thanks to its outperforming net margins.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● Considering the small differences between the analysts' various estimates, the group's business visibility is good.
● The stock is in a well-established, long-term rising trend above the technical support level at 310 DKK
● The company's earnings releases usually do not meet expectations.
● The company's "enterprise value to sales" ratio is among the highest in the world.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
